MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202441036594 A) filed by Sri Ramachandra Institute Of Higher Education And Research, Chennai, Tamil Nadu, on May 8, 2024, for 'a process of combo nanoformulation for the delivery of combo drugs (decursin and enzalutamide) elastin nanogels for prostate cancer therapy and product thereof.'
Inventor(s) include Vinoth Kumar Lakshmanan; Gulzar Ahmed Rather; Satish Srinivas Kondaveeti; and Kumaresan Natarajan.
The application for the patent was published on Nov. 14, under issue no. 46/2025.
According to the abstract released by the Intellectual Property India: "The present invention discloses a process of preparation of decursin and enzalutamide drug incorporated elastin nanogel for prostate cancer therapy, comprises of following steps; a. preparation of oil phase comprises of dissolving enzalutamide and elastin nanogel in Dichloromethane (DCM)/Dimethyl sulfoxide (DMSO) to form oil phase; b. adding decursin drug into the oil phase to form a mixture; c. subjecting the mixture to homogenization to form W1/O emulsion; d. incorporating the W1/O emulsion into polyvinyl alcohol (PVA) solution followed by homogenization to form W1/O/W2 emulsion; e. stirring the W1/O/W2 emulsion at room temperature for 5 hours followed by centrifugation to obtain pellet of decursin and enzalutamide drug incorporated elastin nanogel followed by purification with a dialysis membrane and storing in an air tight container. The present invention also discloses a decursin and enzalutamide drug incorporated elastin nanogel for prostate cancer therapy prepared by the process as described above."
Disclaimer: Curated by HT Syndication.
